Drum Hill Capital LLC Makes New $214,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Drum Hill Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, Holdings Channel reports. The fund purchased 300 shares of the biopharmaceutical company’s stock, valued at approximately $214,000.

A number of other large investors have also recently modified their holdings of REGN. Sequoia Financial Advisors LLC increased its position in Regeneron Pharmaceuticals by 14.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,740 shares of the biopharmaceutical company’s stock valued at $1,829,000 after purchasing an additional 218 shares during the period. Private Advisor Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.0% during the third quarter. Private Advisor Group LLC now owns 5,361 shares of the biopharmaceutical company’s stock valued at $5,635,000 after purchasing an additional 303 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in Regeneron Pharmaceuticals by 21.1% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 3,007 shares of the biopharmaceutical company’s stock worth $3,161,000 after buying an additional 524 shares in the last quarter. Silver Oak Securities Incorporated lifted its holdings in Regeneron Pharmaceuticals by 523.5% during the third quarter. Silver Oak Securities Incorporated now owns 929 shares of the biopharmaceutical company’s stock worth $969,000 after buying an additional 780 shares during the period. Finally, Heritage Oak Wealth Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $371,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.6 %

NASDAQ:REGN opened at $700.33 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company’s fifty day moving average price is $699.40 and its 200-day moving average price is $883.75. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The firm has a market capitalization of $76.56 billion, a P/E ratio of 18.29, a PEG ratio of 2.30 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $11.86 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th.

Analyst Ratings Changes

Several research firms have recently commented on REGN. Barclays reduced their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Bernstein Bank decreased their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Oppenheimer cut their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.